Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2005 1
2006 1
2012 2
2013 4
2014 4
2017 5
2018 5
2019 3
2020 10
2021 8
2022 7
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry.
Bernal T, Moreno AF, de LaIglesia A, Benavente C, García-Noblejas A, Belmonte DG, Riaza R, Salamero O, Foncillas MA, Roldán A, Concepción VN, González LL, Bergua Burgués JM, Lorente de Uña S, Rodríguez-Macías G, de la Fuente Burguera A, García Pérez MJ, López-Lorenzo JL, Martínez P, Aláez C, Callejas M, Martínez-Chamorro C, Roca JR, Barciela LA, Mena Durán AV, Gómez Correcha K, Lavilla Rubira E, Amigo ML, Vall-Llovera F, Garrido A, García-Fortes M, de Miguel Llorente D, Leonardo AA, Cervero C, Jordá RC, Pérez-Encinas MM, Zarzuela MP, Figuera A, Rad G, Martínez-Cuadrón D, Montesinos P. Bernal T, et al. Among authors: garrido a. Cancer Med. 2023 Jul;12(14):14892-14901. doi: 10.1002/cam4.6120. Epub 2023 May 22. Cancer Med. 2023. PMID: 37212507 Free PMC article.
Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced Doses of Post-Transplantation Cyclophosphamide: Challenges and Review of the Literature.
García-Cadenas I, Redondo S, Esquirol A, Portos JM, Novelli S, Saavedra S, Moreno C, Garrido A, Oñate G, López J, Caballero AC, Miqueleiz S, Arguello-Tomas M, Briones J, Sierra J, Martino R. García-Cadenas I, et al. Among authors: garrido a. Transplant Cell Ther. 2023 Jul;29(7):473.e1-473.e6. doi: 10.1016/j.jtct.2023.04.008. Epub 2023 Apr 20. Transplant Cell Ther. 2023. PMID: 37086849 Review.
Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort.
Oñate G, Pratcorona M, Garrido A, Artigas-Baleri A, Bataller A, Tormo M, Arnan M, Vives S, Coll R, Salamero O, Vall-Llovera F, Sampol A, Garcia A, Cervera M, Avila SG, Bargay J, Ortín X, Nomdedéu JF, Esteve J, Sierra J; Spanish Cooperative Group for the Study and Treatment of Acute Leukemias and Myelodysplasias (CETLAM). Oñate G, et al. Among authors: garrido a. Blood Cancer J. 2023 May 5;13(1):69. doi: 10.1038/s41408-023-00839-1. Blood Cancer J. 2023. PMID: 37147301 Free PMC article.
Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.
Sobas M, Knopinska-Posluszny W, Piątkowska-Jakubas B, García-Álvarez F, Díez MEA, Caballero M, Martínez-Cuadrón D, Aguiar E, González-Campos J, Garrido A, Algarra L, Salamero O, de la Serna J, Sayas MJ, Perez-Encinas MM, Vives S, Vidriales B, Labrador J, Prado AI, Celebrin L, Mayer J, Brioso J, de Laiglesia A, Bergua JM, Amigo ML, Rodriguez-Medina C, Polo M, Pluta A, Cichocka E, Skarupski M, Sanz MA, Wierzbowska A, Montesinos P. Sobas M, et al. Among authors: garrido a. Ann Hematol. 2024 Feb;103(2):451-461. doi: 10.1007/s00277-023-05582-y. Epub 2023 Dec 19. Ann Hematol. 2024. PMID: 38110588 Free PMC article.
Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1.
Oñate G, Bataller A, Garrido A, Hoyos M, Arnan M, Vives S, Coll R, Tormo M, Sampol A, Escoda L, Salamero O, Garcia A, Bargay J, Aljarilla A, Nomdedeu JF, Esteve J, Sierra J, Pratcorona M. Oñate G, et al. Among authors: garrido a. Blood Adv. 2022 Feb 8;6(3):882-890. doi: 10.1182/bloodadvances.2020004136. Blood Adv. 2022. PMID: 34516636 Free PMC article.
FcγRIIb expression in early stage chronic lymphocytic leukemia.
Bosch R, Mora A, Vicente EP, Ferrer G, Jansà S, Damle R, Gorlatov S, Rai K, Montserrat E, Nomdedeu J, Pratcorona M, Blanco L, Saavedra S, Garrido A, Esquirol A, Garcia I, Granell M, Martino R, Delgado J, Sierra J, Chiorazzi N, Moreno C. Bosch R, et al. Among authors: garrido a. Leuk Lymphoma. 2017 Nov;58(11):2642-2648. doi: 10.1080/10428194.2017.1307981. Epub 2017 Apr 4. Leuk Lymphoma. 2017. PMID: 28372509 Free PMC article.
European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol.
Bataller A, Garrido A, Guijarro F, Oñate G, Diaz-Beyá M, Arnan M, Tormo M, Vives S, de Llano MPQ, Coll R, Gallardo D, Vall-Llovera F, Escoda L, Garcia-Guiñon A, Salamero O, Sampol A, Merchan BM, Bargay J, Castaño-Díez S, Esteban D, Oliver-Caldés A, Rivero A, Mozas P, López-Guerra M, Pratcorona M, Zamora L, Costa D, Rozman M, Nomdedéu JF, Colomer D, Brunet S, Sierra J, Esteve J. Bataller A, et al. Among authors: garrido a. Blood Adv. 2022 Feb 22;6(4):1193-1206. doi: 10.1182/bloodadvances.2021005585. Blood Adv. 2022. PMID: 34911079 Free PMC article.
Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges.
Redondo S, Esquirol A, Novelli S, Caballero AC, Garrido A, Oñate G, López J, Moreno C, Saavedra SD, Granell M, Briones J, Sierra J, Martino R, García-Cadenas I. Redondo S, et al. Among authors: garrido a. Transplant Cell Ther. 2022 Jan;28(1):43.e1-43.e5. doi: 10.1016/j.jtct.2021.10.015. Epub 2021 Oct 29. Transplant Cell Ther. 2022. PMID: 34757054 Free article.
52 results